Physician profile
Olga Lerner
NPI 1902093693
$2,646.70
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $394 · 2021: $768 · 2022: $238 · 2023: $180 · 2024: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.22 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $416.09 | 2019-2022 | |
| Novo Nordisk INC | $356.17 | 2019-2023 | Tresiba, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.39 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $236.17 | 2019-2022 | |
| Mannkind Corporation | $224.66 | 2019-2021 | |
| Abbott Laboratories | $197.65 | 2020-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $167.13 | 2019-2023 | Mounjaro, Trulicity |
| Sanofi-Aventis U.S. LLC | $138.55 | 2019-2020 | |
| Glaxosmithkline, LLC. | $97.30 | 2019-2020 | |
| Medtronic, INC. | $75.85 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Dexcom, INC. | $58.52 | 2021-2024 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $51.64 | 2019 | |
| Shire North American Group INC | $46.68 | 2019 | |
| Beta Bionics, INC. | $46.09 | 2024 | Ilet Bionic Pancreas |
| Bayer Healthcare Pharmaceuticals INC. | $34.28 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $34.26 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $32.69 | 2022 | |
| Zealand Pharma US, INC. | $32.13 | 2021-2022 | |
| Valeritas, INC. | $24.43 | 2019 | |
| Corcept Therapeutics | $19.51 | 2019 | |
| Amarin Pharma, INC. | $19.32 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2023 | Evkeeza |
| Xeris Pharmaceuticals, INC. | $16.70 | 2021 | |
| Ibsa Pharma INC. | $15.74 | 2020 | |
| Tandem Diabetes Care, INC. | $14.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.